IOI Pioneers Drug Therapies With Breakthrough Ketone Ester Technology

February 13, 2025 -- IOI Corporation Berhad (IOI), through our German subsidiary KetoLipix Therapeutics GmbH (KetoLipix), is leading pharmaceutical innovation by developing drug therapies for conditions with high unmet medical need, leveraging KetoLipix’s breakthrough ketone ester technology.

(File pic by IOI Corporation).

KetoLipix, a spin-off of our German subsidiary IOI Oleo GmbH, has successfully designed and developed a diverse portfolio of ketone esters to provide novel and unconventional treatments for high-need patients. The company particularly targets drug-resistant epilepsy in children as the lead indication, but other forms of metabolic and neurological conditions are also expected to be amenable to ketone ester therapy.

KetoLipix’s proprietary chemical Core Shell Technology provides non-toxic ketone esters with a high ketogenic load, favourable taste, predictable sustained-release properties, food compatibility and optimal tolerability. This innovation is designed to make it easier, safer and more effective for patients to integrate the products into their daily routines.

Chief Executive Officer of KetoLipix Mr Mark Tuchen stated on the progress of KetoLipix since its inception as a biotech start-up in 2022: “I am delighted that we have successfully formed a team of highly experienced and distinguished scientists who have already made great progress in selecting and profiling development candidates from our portfolio of compounds. Expertise in ketone ester chemistry, pharmaceutical development, clinical strategies and all other fields of drug discovery and development has been combined to establish a strategy for swiftly progressing towards testing our hypotheses in the clinic.” 

To date, KetoLipix has developed 14 patent families, establishing itself as a global leader in ketone ester technology and housing the world’s largest proprietary ketone ester library for use as active pharmaceutical ingredients. The technology leverages KetoLipix’s expertise in ketone ester-based drug discovery alongside IOI Oleo GmbH’s leadership in specialty lipids.

IOI Deputy Group Chief Executive Officer and Chairman of the KetoLipix Board Mr Tan Kean Hua emphasised the significance of this breakthrough technology: “I believe that integrating KetoLipix’s cutting-edge technology with IOI Oleo GmbH’s superior production capabilities and global market access will create a synergistic opportunity for our strategic expansion in the pharmaceutical industry.”

About IOI Oleo GmbH
IOI Oleo GmbH is a prominent European supplier of oleochemical specialties and a leading provider of medium-chain triglycerides (MCTs) across Europe. Headquartered in Hamburg, Germany, the company operates advanced production facilities in Witten and Wittenberge, which have consistently adhered to the highest standards of pharmaceutical Good Manufacturing Practice (GMP) since 2005. Specialising in the production and supply of specialty lipids, active substances, and essential oleochemicals, IOI Oleo GmbH serves diverse industries, including cosmetics, pharmaceuticals, food and technical applications.
www.ioioleo.de

About KetoLipix Therapeutics GmbH
KetoLipix Therapeutics GmbH (KetoLipix) was founded in 2022 as a biotech start-up with the vision to treat diseases and improve patients’ quality of life based on new therapeutic concepts. KetoLipix has established a pipeline of proprietary novel therapeutic active substances from a portfolio of several different classes of ketogenic compounds. KetoLipix aims at addressing unmet medical needs in high-priority disease areas using the innovative chemical Core Shell Technology and high-quality GMP processes.
www.ketolipix.com

For more information, please contact:
KetoLipix Therapeutics GmbH
Name: Dr. Dieter Nachtigall
Position: Chief Operating Officer
Email: [email protected]

If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.